Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : and Pantherna Enter into Technology Evaluation Agreement for Research of mRNA-based Regenerative Medicine

11/14/2021 | 07:10pm EST

TOKYO and Hennigsdorf, Germany, November 15, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO: Klaus Giese, Ph.D., "Pantherna") today announced that the companies have entered into a technology evaluation agreement for the research of mRNA-based regenerative medicine.

Pantherna has a technology platform consisting of unique mRNA molecules (PTXmRNAs) for enhancing the efficiency of mRNA actions in the body, and lipid nanoparticles (PTXΔLNPs) for efficiently delivering mRNA.

Under this agreement, Pantherna's state-of-the-art mRNA platform and Astellas' high drug discovery capabilities will be utilized to promote research on the creation of new programs in the field of regenerative medicine and their application to treatment.

Astellas will be in charge of technology evaluation research aimed at providing drug discovery ideas and creating a therapeutic modality, and Pantherna will provide technical information and prepare candidate compounds for the technology evaluation research.

"We are excited and honored to collaborate with Astellas," said Pantherna's Chief Executive Officer, Klaus Giese, Ph.D. "Astellas is an excellent partner for leveraging the unique aspects of our proprietary therapeutic mRNA technology, and this applied research is very important for the validation and broader application of the Pantherna mRNA technology in indications with high medical need."

"Astellas is engaged in the development of novel therapies using a new modality / technology based on the Focus Area approach strategy," said Taiji Sawamoto, Executive Vice President, Applied Research & Operations, at Astellas. "Pantherna is a leader in this area with a unique technology platform for mRNA. Through this collaboration, we will create an innovative regenerative medicine program with mRNA as a therapeutic modality, and we expect that we will be able to expand the treatment options of various diseases for which there has been no cure thus far."

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 15 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2021 00:09:07 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
01/20ASTELLAS PHARMA : We posted the presentation material for media briefing on Digital Transf..
PU
01/20ASTELLAS PHARMA : Digital Transformation of Astellas Pharma(3,351KB)
PU
01/19Essa Pharma Commences Dosing in Phase 1/2 Clinical Trial of Prostate Cancer Combo Thera..
MT
01/16Glenmark Pharmaceuticals Unit Gets US FDA's Approval for Regadenoson Injection
MT
01/10Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t..
AQ
01/10Modalis Therapeutics and Astellas Pharma End Research Collaboration on Nervous System M..
MT
01/07Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US
MT
01/07Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million..
DJ
01/07Modalis Announces Termination of Research Collaboration on MDL-204
CI
01/06Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration ..
AQ
More news
Financials
Sales 2022 1 334 B 11 728 M 11 728 M
Net income 2022 183 B 1 613 M 1 613 M
Net cash 2022 380 B 3 342 M 3 342 M
P/E ratio 2022 19,7x
Yield 2022 2,59%
Capitalization 3 583 B 31 486 M 31 505 M
EV / Sales 2022 2,40x
EV / Sales 2023 2,12x
Nbr of Employees 15 455
Free-Float -
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 933,50 JPY
Average target price 2 451,67 JPY
Spread / Average Target 26,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa Executive Officer
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.3.37%31 486
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356